RT Journal Article
SR Electronic
T1 Prevalence of heart disease in patients hospitalized for an acute exacerbation of COPD: Impact on clinical outcome. A 6 month follow-up study
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP p547
VO 38
IS Suppl 55
A1 Silvia Fernandez Serrano
A1 Dan Sanchez Berenguer
A1 Jaume Oriol
A1 Ludmila San Vicente
A1 Nuria Galofre
A1 Gemma Beltran
A1 Montse Altimira
A1 Lidia Ortega
YR 2011
UL http://erj.ersjournals.com/content/38/Suppl_55/p547.abstract
AB Aim: In order to analyze the prevalence of heart disease “HD” (known or not) in patients hospitalized due to an acute exacerbation of COPD, we carried out a prospective study.Material and methods: A total of 103 patients were prospectively included. Clinical course and outcome were analyzed during a 6-month follow-up.Assessment of mean length of stay, mortality and hospital readmission was made. ECG, Echocardiography and NTproBNP value were used for the cardiac evaluation.Results: 103 patients (71.83±9.3 years) were recruited, 81% of them with GOLD stage ≥ 3.Thirty-seven patients had a HD (a “newly” disease in 14): group FI. The COPD was alone in 63: group FII.The mean length of stay was 5.74±3.4 days and the in-hospital mortality rate was 2.9%. At 6-month follow-up: the mortality rate was 4.9% and the readmission rate 46.6% (35.5% of early readmission). Between readmitted cases, 56% were in GOLD stage 4.With regard to the cardiac evaluation, the phisical examination (yugular venous distention: 21.1% vs 4.6%, p=0.017; peripheral edema:31.6% vs 12.3%, p=0.022, pulmonary rales: 18.4% vs 2%, p=0.04), the ECG (28.9% vs 10.8%, p=0.030), the ecocardiography (LVEF < 50%: 23.7% vs 6.2%, p=0.014) and NT-proBNP (> 1200 pg/ml: 44.4% vs 13.3%, p=0.003) were more freqüent abnormal in the group FI than in the group FII.Conclusions: 1. The global prevalence of HD in our cohort of patients with an acute exacerbation of COPD was 37%.2. In this setting, physical examination, an abnormal ECG, an EF<50% and a NTproBNP value > 1200pg/mL, could help to identify patients with a probable HD.3. Fifty-six% of readmissions were patients in GOLD stage IV.